-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎WuXi AppTec content team editor
The "tailor-made" therapeutic cancer vaccine VB10.
NEO has outstanding early clinical data, inducing a wide range of T cell responses
in 95% of patients.
2.
Allogeneic T cell immunotherapy ATA188 can prevent multiple sclerosis progression for nearly four years
.
3.
The 24-valent potential "best-in-class" pneumococcal vaccine provides 10-15% additional protection for patients
.
WuXi AppTec content team organizes
VB10.
NEO: Published preliminary data
from a Phase 1/2a clinical trial Nykode Therapeutics has published its proprietary personalized therapeutic DNA cancer vaccine in a Phase 1/2a clinical trial, Therapeutics Initial positive safety and immunogenicity results in patients with advanced or metastatic solid tumors.
Neoantigens are proteins produced by tumor-specific mutations that are not present in normal tissues and may be recognized by the immune system as foreign to cause anti-tumor immune responses, and are potential targets for
cancer immunotherapy.
The vaccine is designed to be produced individually based on the patient's individual neoantigen profile
.
The data released this time shows that VB10.
NEO induced a broad T cell response in 95% of patients, including the expansion of new and pre-existing T cells, with most of the encoded new epitopes being immunogenic and able to induce CD8+ T cell responses
.
In addition, multiple vaccinations were able to increase the breadth and amplitude of the immune response, which was sustained for most T-cell responses for at least a year
.
In terms of security, VB10.
NEO is generally safe and tolerated
in patients with solid tumors.
ATA188: Published Phase 1 clinical trial data
Atara Biotherapeutics updates its allogeneic T cell immunotherapy ATA188 targeting Epstein-Barr virus (EBV), New progress in phase 1 clinical trials for the treatment of patients with progressive multiple sclerosis (MS).
ATA188 is an investigational off-the-shelf allogeneic T cell immunotherapy developed by Atara to specifically target EBV-infected B cells and plasma cells in progressive MS and reduce the attack
on nerve myelin sheaths.
The Phase 1 clinical trial data released this time show that most patients treated with ATA188 achieved long-term and lasting clinical disability improvement, and all patients who achieved stable disease remained stable
for 48 months.
In addition, patients treated with ATA188 and had confirmed improvement in disability showed a significant reduction
in brain atrophy in longitudinal analysis of MRI images at 42 months.
VAX-24: Announced Phase 1/2 Clinical Trial Data
Vaxcyte announced positive data
from a Phase 1/2 clinical trial of its 24-valent pneumococcal conjugate vaccine (PCV) candidate, VAX-24 。 VAX-24 is an investigational 24-valent PCV vaccine candidate for the prevention of invasive pneumococcal disease (IPD) designed to improve standard care
for PCV in children and adults by covering most currently circulating pneumococcal serotypes.
The study evaluated the safety, tolerability and immunogenicity
of VAX-24 in healthy adults aged 18-64 years.
In this clinical trial, VAX-24 demonstrated similar safety and tolerability profiles
to existing standard care for 20-valent PCV at all study doses.
In addition, VAX-24's unique 4 serotypes met efficacy criteria at all doses, and these 4 increased serotypes covered 10-15% of the strains
that cause IPD in the current adult standard of care.
In August 2022, FDA granted Fast Track designation
to VAX-24 for adult indications.
Bria-IMT: Published Phase 1 Clinical Trial DataBriaCell
Therapeutics has published data from a Phase 1 clinical trial of its cell candidate, Bria-IMT, in combination with Incyte's PD-1 inhibitor, retifanlimab, for the treatment of advanced breast cancer
。 Bria-IMT is a human breast cancer cell line expressing Her2/neu and is designed to produce and secrete breast cancer antigens and granulocyte-macrophage colony-stimulating factor (GM-CSF), which promotes dendritic cell-based antigen presentation and activates the immune system
.
In addition, Bria-IMT can directly stimulate anti-tumor CD4+ and CD8+ T cells, further enhancing the anti-tumor immune response
.
This Phase 1 clinical trial has been completed and the results show that the combination therapy of Bria-IMT with retifanlimab showed good safety and tolerability in 12 patients who had failed other therapies with no dose-limiting toxicity
.
Recently, Bria-IMT was granted Fast Track designation
by the FDA.
BP1002: Phase 1/1b clinical trial completed The first patient-administered BP1002 is a neutrally charged, liposome-incorporated antisense RNAi drug that inhibits protein synthesis of Bcl-2 by targeting Bcl-2
at the mRNA level rather than the protein level
。 Bcl-2, a protein involved in blocking programmed cell death, is overexpressed in a variety of tumors, including non-Hodgkin lymphoma and chronic lymphocytic leukemia
.
Tumor cells overexpressing Bcl-2 are resistant to chemotherapy
.
BP1002 is expected to overcome the problem
of venitoclax, the standard of care for patients with acute myeloid leukemia (AML) who are currently not eligible for intensive chemotherapy.
Venitoclax is also an oral Bcl-2 inhibitor that targets the BH3 domain
of the Bcl-2 protein.
Preclinical studies have shown that BP1002 is an effective inhibitor against Bcl-2, and its good safety profile should enable BP1002 to be combined with approved drugs, and that the combination of BP1002 with decitabine is effective
against venetoclax-resistant cells.
MCLA-129: Announced Interim Data
from Phase 1/2 Clinical Trial Merus announced interim data
from its bispecific antibody MCLA-129 in the treatment of advanced non-small cell lung cancer (NSCLC) and other solid tumor patients in clinical Phase 1/2 trials 。 MCLA-129 is a fully human antibody-dependent cytotoxicity (ADCC)-enhanced EGFR/c-MET bispecific antibody with two complementary mechanisms of action: blocking tumor growth and survival pathways to stop its spread, while enhancing immune effector cells to eliminate tumors
.
The data released this time shows that MCLA-129 is safe
and well tolerated.
The antitumor activity
of MCLA-129 has been observed in patients of multiple tumor types who have been previously treated.
Two of the 18 evaluable patients achieved a confirmed partial response (PR), and 4 patients had tumor shrinkage > 20%.
XB002: Announced preliminary data
from Phase 1 clinical trials Exelixis announced preliminary results
of its Phase 1 clinical trial of its next-generation antibody conjugate XB002, which targets tissue factors, in the treatment of advanced solid tumors.
Tissue factors are overexpressed
in a variety of solid tumors.
XB002 binds to tissue factors on tumor cells and is internalized, releasing cytotoxic drugs that lead to the death
of tumor cells.
Previously, targeting tissue factorsThe molecule has limitations in influencing the coagulation cascade, but preclinical studies have shown that XB002 does not affect the coagulation cascade
.
The data presented this time shows that XB002 is well
tolerated at multiple dose levels.
Pharmacokinetic analysis showed that XB002 was able to remain stable after infusion and had the ability to
reach target cells before releasing its cytotoxic drug.
Tipifarnib: Published preliminary data from a Phase 1/2 clinical trial Kura Oncology published its farnetransferase inhibitor tipifarnib in combination with alpelisib for the treatment of HRAS and/
or preliminary data
from a Phase 1/2 clinical trial in patients with PIK3CA-dependent head and neck squamous cell carcinoma (HNSCC).
HRAS is a proto-oncogene, which is a normal gene that can become an oncogene
due to mutation or increased expression.
HRAS is mutated and/or expressed
in certain head and neck squamous cell carcinomas.
Farnesyltransferase is a key enzyme
that regulates HRAS activity.
The published data are the first to demonstrate that this combination therapy can achieve a lasting clinical response
in PIK3CA-dependent HNSCC.
Preclinical data suggest that the therapy has the potential to respond
to approximately 45% of patients with HNSCC tumors overexpressing and/or carrying PIK3CA mutations.
OP-1250: Published preliminary data from a Phase 1/2 clinical trial Olema Oncology has published preliminary data
from a Phase 1/2 clinical trial of its drug candidate, OP-1250, in patients with advanced and/or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer 。 OP-1250 is an oral small molecule drug
with two dual activities: a complete ER antagonist (CERAN) and a selective ER degrader (SERD).
The data released this time show that OP-1250 is well tolerated, with good pharmacokinetic (PK) and drug exposure levels
.
In addition, OP-1250 has demonstrated strong antitumor activity and long-lasting benefits, with lesions shrinking in 41% of patients and PR in 6 of 57 patients with evaluable efficacy (4 confirmed, 2 unconfirmed).
Previously, OP-1250 had received Fast Track designation
from the FDA.
EPI-7386: Published Phase 1/2 Clinical Trial Data
ESSA Pharma Announced Its Second-Generation Antiandrogen Drug EPI-7386 in combination with enzalutamide The latest data
from the first two cohorts of clinical phase 1/2 trials to treat patients with metastatic castration-resistant prostate cancer (mCRPC).
EPI-7386 is an oral small molecule inhibitor
of the N-terminal domain of highly selective androgen receptors.
The results of the study showed that the combination therapy was well tolerated, with a safety profile consistent with second-generation antiandrogen drugs, and no dose-limiting toxicities
were observed.
Previously, the FDA granted EPI-7386 fast-track designation for the treatment of adult male patients
with mCRPC who are resistant to standard care treatments.
Fadraciclib: Published preliminary data from a Phase 1/2 clinical trial Cyclacel Pharmaceuticals has published preliminary data
from its oral drug candidate, fadraciclib, for the treatment of patients with advanced solid tumors and lymphomas
。 Fadraciclib is a cyclin-dependent kinase (CDK) 2/9 inhibitor
.
CDK is essential for cell cycle control and transcriptional regulation, with CDK2 driving cell cycle transitions and CDK9 regulating gene transcription
.
Fadraciclib can cause apoptosis and death of cancer cells by inhibiting CDK2 and
CDK9.
The data released this time show that fadraciclib is well tolerated, with PR achieved disease stability (SD)
in 2 of the treated T-cell lymphoma patients and 11 of the 15 patients with various solid tumors who were evaluated achieved PR.
To date, no dose-limiting toxicity
has been observed.
RVU120: Published preliminary data from a Phase 1 clinical trial Ryvu Therapeutics has published preliminary data
from its Phase 1/2 clinical trial of its CDK8/19 inhibitor RVU120 in patients with relapsed/refractory metastases or advanced solid tumors.
Results showed that RVU120 was well tolerated at all evaluated doses, and no dose-limiting toxicity
was observed.
Of the 11 patients who could be evaluated, 4 achieved SD, and 3 achieved SD
for more than 4 months.
Preclinical data show that RVU120 has the potential to
enhance ADCC to promote drug therapy.
Baxdrostat: CinCor
Pharma has published data
from its Phase 1 clinical trial of baxdrostat for the treatment of hypertension 。 Baxdrostat (CIN-107) is a highly selective oral small molecule aldosterone synthase inhibitor that acts on the renin-angiotensin-aldosterone regulatory system for the treatment of drug-resistant hypertension and essential hyperaldosteronism
.
The results of the published study showed that baxdrostat had good tolerability and pharmacokinetic profiles, and its half-life supported once-daily oral administration
.
In addition, a dose-dependent reduction in plasma aldosterone and no effect on cortisol enhances the effect
of baxdrostat in selectively blocking aldosterone synthase.
MORF-057: Phase 1 clinical trial data
published Morphic Therapeutic published its selective oral small molecule Results
of a Phase 1 clinical trial of the α4β7 integrin inhibitor MORF-057 for the treatment of inflammatory bowel disease (IBD).
MORF-057 is designed to block the interaction between α4β7 on the surface of lymphocytes and the mucosal endothelial cell ligand MAdCAM-1, thereby significantly reducing the migration of lymphocytes from the blood to the intestinal mucosal tissue and causing IBD-associated inflammation
.
In this phase 1 study, all doses were well tolerated, no safety signals were found, and good pharmacokinetic profiles
were observed.
ALRN-6924: Published Phase 1 Clinical Trial Data
Aileron Therapeutics announced the results
of its Phase 1 clinical trial of ALRN-6924 in healthy subjects 。 ALRN-6924 is a potential "first-in-class" dual MDM2/MDMX inhibitor intended as a novel selective chemoprotective agent
for patients with p53-mutant cancers.
ALRN-6924 is designed to induce cell cycle arrest by activating p53, which in turn upregulates p21, a known cell replication cycle inhibitor, to protect normal, healthy cells from damage
caused by chemotherapy.
The data presented this time show that ALRN-6924 has the potential to
prevent chemotherapy-induced neutropenia, thrombocytopenia, anemia, and chemotherapy-induced hair loss.
ALRN-6924 has a greater degree of action and lasts longer
at higher doses.
In addition, ALRN-6924 showed similar safety, pharmacokinetics, and pharmacodynamics at 3-minute intravenous bolus and 1-hour intravenous infusion, providing a basis for
future development of simplified bolus dosing.
QBS72S: Completed Phase 1 clinical trial enrollment QBS72S
is a novel potential "first-in-class" chemotherapeutic agent that mimics aromatic amino acidsIt is used to treat advanced solid tumors
.
QBS72S is able to be taken up into cells by L-type amino acid transporter 1 (LAT1), enabling it to cross the blood-brain barrier (BBB).
Most aggressive cancers express high levels of LAT1, which is often associated with
a poor prognosis.
As a result, QBS72S is able to selectively target multiple types of fast-growing cancer cells
.
Once inside the cell, QBS72S causes double-stranded DNA to break, causing cell death
.
ciforadenant (CPI-444): Initiation of Phase 1b/2 clinical trial
Ciforadenant (CPI-444) is an oral A2A receptor small molecule inhibitor designed to bind adenosine to A2A receptors by blocking adenosine in the tumor microenvironment, Disable
the tumor's ability to destroy the immune system.
Adenosine is a metabolite of adenosine triphosphate (ATP), produced in the tumor microenvironment, which binds to adenosine A2A receptors present on immune cells and blocks their activity
.
Preclinical studies have shown that the use of ciforadenant in combination with CTLA-4 inhibitors and PD-1 inhibitors can control or completely eliminate tumors
.
The Phase 1b/2 clinical trial was conducted to evaluate the efficacy
of ciforadenant in combination with the CTLA-4 inhibitor ipilimumab and the PD-1 inhibitor nivolumab for the first-line treatment of renal cell carcinoma.
WuXi AppTec provides integrated, end-to-end new drug R&D and manufacturing services to the global biopharmaceutical industry, covering chemical drug R&D and manufacturing, biological research, preclinical testing and clinical trial R&D, cell and gene therapy R&D, testing and manufacturing
.
If you have related business needs, please click the picture below to fill in the specific information
.
▲If you have any business needs, please long press to scan the QR code above, or
Highlights of this issue
The "tailor-made" therapeutic cancer vaccine VB10.
NEO has outstanding early clinical data, inducing a wide range of T cell responses
in 95% of patients.
2.
Allogeneic T cell immunotherapy ATA188 can prevent multiple sclerosis progression for nearly four years
.
3.
The 24-valent potential "best-in-class" pneumococcal vaccine provides 10-15% additional protection for patients
.
WuXi AppTec content team organizes
VB10.
NEO: Published preliminary data
from a Phase 1/2a clinical trial Nykode Therapeutics has published its proprietary personalized therapeutic DNA cancer vaccine in a Phase 1/2a clinical trial, Therapeutics Initial positive safety and immunogenicity results in patients with advanced or metastatic solid tumors.
Neoantigens are proteins produced by tumor-specific mutations that are not present in normal tissues and may be recognized by the immune system as foreign to cause anti-tumor immune responses, and are potential targets for
cancer immunotherapy.
The vaccine is designed to be produced individually based on the patient's individual neoantigen profile
.
The data released this time shows that VB10.
NEO induced a broad T cell response in 95% of patients, including the expansion of new and pre-existing T cells, with most of the encoded new epitopes being immunogenic and able to induce CD8+ T cell responses
.
In addition, multiple vaccinations were able to increase the breadth and amplitude of the immune response, which was sustained for most T-cell responses for at least a year
.
In terms of security, VB10.
NEO is generally safe and tolerated
in patients with solid tumors.
ATA188: Published Phase 1 clinical trial data
Atara Biotherapeutics updates its allogeneic T cell immunotherapy ATA188 targeting Epstein-Barr virus (EBV), New progress in phase 1 clinical trials for the treatment of patients with progressive multiple sclerosis (MS).
ATA188 is an investigational off-the-shelf allogeneic T cell immunotherapy developed by Atara to specifically target EBV-infected B cells and plasma cells in progressive MS and reduce the attack
on nerve myelin sheaths.
The Phase 1 clinical trial data released this time show that most patients treated with ATA188 achieved long-term and lasting clinical disability improvement, and all patients who achieved stable disease remained stable
for 48 months.
In addition, patients treated with ATA188 and had confirmed improvement in disability showed a significant reduction
in brain atrophy in longitudinal analysis of MRI images at 42 months.
VAX-24: Announced Phase 1/2 Clinical Trial Data
Vaxcyte announced positive data
from a Phase 1/2 clinical trial of its 24-valent pneumococcal conjugate vaccine (PCV) candidate, VAX-24 。 VAX-24 is an investigational 24-valent PCV vaccine candidate for the prevention of invasive pneumococcal disease (IPD) designed to improve standard care
for PCV in children and adults by covering most currently circulating pneumococcal serotypes.
The study evaluated the safety, tolerability and immunogenicity
of VAX-24 in healthy adults aged 18-64 years.
In this clinical trial, VAX-24 demonstrated similar safety and tolerability profiles
to existing standard care for 20-valent PCV at all study doses.
In addition, VAX-24's unique 4 serotypes met efficacy criteria at all doses, and these 4 increased serotypes covered 10-15% of the strains
that cause IPD in the current adult standard of care.
In August 2022, FDA granted Fast Track designation
to VAX-24 for adult indications.
Bria-IMT: Published Phase 1 Clinical Trial DataBriaCell
Therapeutics has published data from a Phase 1 clinical trial of its cell candidate, Bria-IMT, in combination with Incyte's PD-1 inhibitor, retifanlimab, for the treatment of advanced breast cancer
。 Bria-IMT is a human breast cancer cell line expressing Her2/neu and is designed to produce and secrete breast cancer antigens and granulocyte-macrophage colony-stimulating factor (GM-CSF), which promotes dendritic cell-based antigen presentation and activates the immune system
.
In addition, Bria-IMT can directly stimulate anti-tumor CD4+ and CD8+ T cells, further enhancing the anti-tumor immune response
.
This Phase 1 clinical trial has been completed and the results show that the combination therapy of Bria-IMT with retifanlimab showed good safety and tolerability in 12 patients who had failed other therapies with no dose-limiting toxicity
.
Recently, Bria-IMT was granted Fast Track designation
by the FDA.
BP1002: Phase 1/1b clinical trial completed The first patient-administered BP1002 is a neutrally charged, liposome-incorporated antisense RNAi drug that inhibits protein synthesis of Bcl-2 by targeting Bcl-2
at the mRNA level rather than the protein level
。 Bcl-2, a protein involved in blocking programmed cell death, is overexpressed in a variety of tumors, including non-Hodgkin lymphoma and chronic lymphocytic leukemia
.
Tumor cells overexpressing Bcl-2 are resistant to chemotherapy
.
BP1002 is expected to overcome the problem
of venitoclax, the standard of care for patients with acute myeloid leukemia (AML) who are currently not eligible for intensive chemotherapy.
Venitoclax is also an oral Bcl-2 inhibitor that targets the BH3 domain
of the Bcl-2 protein.
Preclinical studies have shown that BP1002 is an effective inhibitor against Bcl-2, and its good safety profile should enable BP1002 to be combined with approved drugs, and that the combination of BP1002 with decitabine is effective
against venetoclax-resistant cells.
MCLA-129: Announced Interim Data
from Phase 1/2 Clinical Trial Merus announced interim data
from its bispecific antibody MCLA-129 in the treatment of advanced non-small cell lung cancer (NSCLC) and other solid tumor patients in clinical Phase 1/2 trials 。 MCLA-129 is a fully human antibody-dependent cytotoxicity (ADCC)-enhanced EGFR/c-MET bispecific antibody with two complementary mechanisms of action: blocking tumor growth and survival pathways to stop its spread, while enhancing immune effector cells to eliminate tumors
.
The data released this time shows that MCLA-129 is safe
and well tolerated.
The antitumor activity
of MCLA-129 has been observed in patients of multiple tumor types who have been previously treated.
Two of the 18 evaluable patients achieved a confirmed partial response (PR), and 4 patients had tumor shrinkage > 20%.
XB002: Announced preliminary data
from Phase 1 clinical trials Exelixis announced preliminary results
of its Phase 1 clinical trial of its next-generation antibody conjugate XB002, which targets tissue factors, in the treatment of advanced solid tumors.
Tissue factors are overexpressed
in a variety of solid tumors.
XB002 binds to tissue factors on tumor cells and is internalized, releasing cytotoxic drugs that lead to the death
of tumor cells.
Previously, targeting tissue factorsThe molecule has limitations in influencing the coagulation cascade, but preclinical studies have shown that XB002 does not affect the coagulation cascade
.
The data presented this time shows that XB002 is well
tolerated at multiple dose levels.
Pharmacokinetic analysis showed that XB002 was able to remain stable after infusion and had the ability to
reach target cells before releasing its cytotoxic drug.
Tipifarnib: Published preliminary data from a Phase 1/2 clinical trial Kura Oncology published its farnetransferase inhibitor tipifarnib in combination with alpelisib for the treatment of HRAS and/
or preliminary data
from a Phase 1/2 clinical trial in patients with PIK3CA-dependent head and neck squamous cell carcinoma (HNSCC).
HRAS is a proto-oncogene, which is a normal gene that can become an oncogene
due to mutation or increased expression.
HRAS is mutated and/or expressed
in certain head and neck squamous cell carcinomas.
Farnesyltransferase is a key enzyme
that regulates HRAS activity.
The published data are the first to demonstrate that this combination therapy can achieve a lasting clinical response
in PIK3CA-dependent HNSCC.
Preclinical data suggest that the therapy has the potential to respond
to approximately 45% of patients with HNSCC tumors overexpressing and/or carrying PIK3CA mutations.
OP-1250: Published preliminary data from a Phase 1/2 clinical trial Olema Oncology has published preliminary data
from a Phase 1/2 clinical trial of its drug candidate, OP-1250, in patients with advanced and/or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer 。 OP-1250 is an oral small molecule drug
with two dual activities: a complete ER antagonist (CERAN) and a selective ER degrader (SERD).
The data released this time show that OP-1250 is well tolerated, with good pharmacokinetic (PK) and drug exposure levels
.
In addition, OP-1250 has demonstrated strong antitumor activity and long-lasting benefits, with lesions shrinking in 41% of patients and PR in 6 of 57 patients with evaluable efficacy (4 confirmed, 2 unconfirmed).
Previously, OP-1250 had received Fast Track designation
from the FDA.
EPI-7386: Published Phase 1/2 Clinical Trial Data
ESSA Pharma Announced Its Second-Generation Antiandrogen Drug EPI-7386 in combination with enzalutamide The latest data
from the first two cohorts of clinical phase 1/2 trials to treat patients with metastatic castration-resistant prostate cancer (mCRPC).
EPI-7386 is an oral small molecule inhibitor
of the N-terminal domain of highly selective androgen receptors.
The results of the study showed that the combination therapy was well tolerated, with a safety profile consistent with second-generation antiandrogen drugs, and no dose-limiting toxicities
were observed.
Previously, the FDA granted EPI-7386 fast-track designation for the treatment of adult male patients
with mCRPC who are resistant to standard care treatments.
Fadraciclib: Published preliminary data from a Phase 1/2 clinical trial Cyclacel Pharmaceuticals has published preliminary data
from its oral drug candidate, fadraciclib, for the treatment of patients with advanced solid tumors and lymphomas
。 Fadraciclib is a cyclin-dependent kinase (CDK) 2/9 inhibitor
.
CDK is essential for cell cycle control and transcriptional regulation, with CDK2 driving cell cycle transitions and CDK9 regulating gene transcription
.
Fadraciclib can cause apoptosis and death of cancer cells by inhibiting CDK2 and
CDK9.
The data released this time show that fadraciclib is well tolerated, with PR achieved disease stability (SD)
in 2 of the treated T-cell lymphoma patients and 11 of the 15 patients with various solid tumors who were evaluated achieved PR.
To date, no dose-limiting toxicity
has been observed.
RVU120: Published preliminary data from a Phase 1 clinical trial Ryvu Therapeutics has published preliminary data
from its Phase 1/2 clinical trial of its CDK8/19 inhibitor RVU120 in patients with relapsed/refractory metastases or advanced solid tumors.
Results showed that RVU120 was well tolerated at all evaluated doses, and no dose-limiting toxicity
was observed.
Of the 11 patients who could be evaluated, 4 achieved SD, and 3 achieved SD
for more than 4 months.
Preclinical data show that RVU120 has the potential to
enhance ADCC to promote drug therapy.
Baxdrostat: CinCor
Pharma has published data
from its Phase 1 clinical trial of baxdrostat for the treatment of hypertension 。 Baxdrostat (CIN-107) is a highly selective oral small molecule aldosterone synthase inhibitor that acts on the renin-angiotensin-aldosterone regulatory system for the treatment of drug-resistant hypertension and essential hyperaldosteronism
.
The results of the published study showed that baxdrostat had good tolerability and pharmacokinetic profiles, and its half-life supported once-daily oral administration
.
In addition, a dose-dependent reduction in plasma aldosterone and no effect on cortisol enhances the effect
of baxdrostat in selectively blocking aldosterone synthase.
MORF-057: Phase 1 clinical trial data
published Morphic Therapeutic published its selective oral small molecule Results
of a Phase 1 clinical trial of the α4β7 integrin inhibitor MORF-057 for the treatment of inflammatory bowel disease (IBD).
MORF-057 is designed to block the interaction between α4β7 on the surface of lymphocytes and the mucosal endothelial cell ligand MAdCAM-1, thereby significantly reducing the migration of lymphocytes from the blood to the intestinal mucosal tissue and causing IBD-associated inflammation
.
In this phase 1 study, all doses were well tolerated, no safety signals were found, and good pharmacokinetic profiles
were observed.
ALRN-6924: Published Phase 1 Clinical Trial Data
Aileron Therapeutics announced the results
of its Phase 1 clinical trial of ALRN-6924 in healthy subjects 。 ALRN-6924 is a potential "first-in-class" dual MDM2/MDMX inhibitor intended as a novel selective chemoprotective agent
for patients with p53-mutant cancers.
ALRN-6924 is designed to induce cell cycle arrest by activating p53, which in turn upregulates p21, a known cell replication cycle inhibitor, to protect normal, healthy cells from damage
caused by chemotherapy.
The data presented this time show that ALRN-6924 has the potential to
prevent chemotherapy-induced neutropenia, thrombocytopenia, anemia, and chemotherapy-induced hair loss.
ALRN-6924 has a greater degree of action and lasts longer
at higher doses.
In addition, ALRN-6924 showed similar safety, pharmacokinetics, and pharmacodynamics at 3-minute intravenous bolus and 1-hour intravenous infusion, providing a basis for
future development of simplified bolus dosing.
QBS72S: Completed Phase 1 clinical trial enrollment QBS72S
is a novel potential "first-in-class" chemotherapeutic agent that mimics aromatic amino acidsIt is used to treat advanced solid tumors
.
QBS72S is able to be taken up into cells by L-type amino acid transporter 1 (LAT1), enabling it to cross the blood-brain barrier (BBB).
Most aggressive cancers express high levels of LAT1, which is often associated with
a poor prognosis.
As a result, QBS72S is able to selectively target multiple types of fast-growing cancer cells
.
Once inside the cell, QBS72S causes double-stranded DNA to break, causing cell death
.
ciforadenant (CPI-444): Initiation of Phase 1b/2 clinical trial
Ciforadenant (CPI-444) is an oral A2A receptor small molecule inhibitor designed to bind adenosine to A2A receptors by blocking adenosine in the tumor microenvironment, Disable
the tumor's ability to destroy the immune system.
Adenosine is a metabolite of adenosine triphosphate (ATP), produced in the tumor microenvironment, which binds to adenosine A2A receptors present on immune cells and blocks their activity
.
Preclinical studies have shown that the use of ciforadenant in combination with CTLA-4 inhibitors and PD-1 inhibitors can control or completely eliminate tumors
.
The Phase 1b/2 clinical trial was conducted to evaluate the efficacy
of ciforadenant in combination with the CTLA-4 inhibitor ipilimumab and the PD-1 inhibitor nivolumab for the first-line treatment of renal cell carcinoma.
WuXi AppTec provides integrated, end-to-end new drug R&D and manufacturing services to the global biopharmaceutical industry, covering chemical drug R&D and manufacturing, biological research, preclinical testing and clinical trial R&D, cell and gene therapy R&D, testing and manufacturing
.
If you have related business needs, please click the picture below to fill in the specific information
.
▲If you have any business needs, please long press to scan the QR code above, or
